Skip to content
Colorectal Cancer Clinical Trials

Chicago, Illinois

Colorectal cancer clinical trials in Chicago, IL

53 colorectal cancer studies are recruiting participants at sites in Chicago as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Chicago at a glance

  • 53 studies are recruiting at a site in Chicago.
  • By phase: Phase 1 (8), Phase 1/2 (8), Phase 2 (7), Phase 2/3 (2), Phase 3 (9), Phase 4 (1), No phase (8), Observational (10). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (27), university, hospital or other (26).
  • Most recent update to one of these records: November 16, 2026.

Studies recruiting in Chicago

Basic details from each study's public record (the 30 most recently updated of 53). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study sites
    Northwestern Medicine Cancer Center Old Irving Park · Northwestern University · University of Chicago Comprehensive Cancer Center
    Registry record
    NCT05863195 · updated
  2. Shield Post-Approval Study Protocol

    • Observational
    • Ages 45 to 81
    • All sexes
    Sponsor
    Guardant Health, Inc.
    Study site
    GI Solutions of Illinois
    Registry record
    NCT06880055 · updated
  3. Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer

    • Observational
    • Ages 60 and older
    • All sexes
    Sponsor
    Wake Forest University Health Sciences
    Study site
    John H Stroger Jr Hospital of Cook County
    Registry record
    NCT03998202 · updated
  4. Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Summit Therapeutics
    Registry record
    NCT07228832 · updated
  5. FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Oncolytics Biotech
    Study site
    Northwestern Memorial Hospital
    Registry record
    NCT07446322 · updated
  6. Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

    • No phase
    • Ages 45 to 70
    • All sexes
    Sponsor
    NRG Oncology
    Study site
    John H Stroger Jr Hospital of Cook County
    Registry record
    NCT05080673 · updated
  7. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Advocate Illinois Masonic Medical Center · John H Stroger Jr Hospital of Cook County · Mount Sinai Hospital Medical Center
    Registry record
    NCT05174169 · updated
  8. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Advocate Illinois Masonic Medical Center · John H Stroger Jr Hospital of Cook County · Mount Sinai Hospital Medical Center
    Registry record
    NCT05334069 · updated
  9. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Wake Forest University Health Sciences
    Study sites
    Advocate Illinois Masonic Medical Center · John H Stroger Jr Hospital of Cook County
    Registry record
    NCT06418204 · updated
  10. Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Advocate Illinois Masonic Medical Center
    Registry record
    NCT07283939 · updated
  11. Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    University of Illinois
    Registry record
    NCT05673148 · updated
  12. Family Communications After Genetic Testing

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Advocate Illinois Masonic Medical Center
    Registry record
    NCT07143487 · updated
  13. A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    The University of Chicago Medical Center
    Registry record
    NCT07416552 · updated
  14. FITting Non-invasive Tests in Lynch Syndrome Surveillance

    • No phase
    • Ages 20 to 80
    • All sexes
    Sponsor
    University of Chicago
    Study site
    The University of Chicago Medical Center
    Registry record
    NCT06898996 · updated
  15. A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study site
    University of Illinois Cancer Center
    Registry record
    NCT07284849 · updated
  16. A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    University of Chicago Medical Center /ID# 271688
    Registry record
    NCT06820463 · updated
  17. A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    University of Chicago Medical Center
    Registry record
    NCT07221357 · updated
  18. Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Delcath Systems Inc.
    Study site
    Northwestern University - Feinberg School of Medicine
    Registry record
    NCT06607458 · updated
  19. A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    University of Chicago Medical Center /ID# 279365
    Registry record
    NCT07525206 · updated
  20. Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    City of Hope Medical Center
    Study site
    City of Hope at Illinois Chicago Downtown
    Registry record
    NCT07595874 · updated
  21. SMP-3124LP in Adults With Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Sumitomo Pharma America, Inc.
    Study sites
    Northwestern Medicine Cancer Center · The University of Chicago
    Registry record
    NCT06526819 · updated
  22. A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    University of Chicago Medical Center /ID# 274742
    Registry record
    NCT07023289 · updated
  23. Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    Illinois Cancer Specialists
    Registry record
    NCT07222800 · updated
  24. AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Avacta Life Sciences Ltd
    Study site
    The University of Chicago
    Registry record
    NCT07454642 · updated
  25. Colonoscopy vs Stool Testing for Older Adults With Colon Polyps

    • No phase
    • Ages 65 to 82
    • All sexes
    Sponsor
    Dartmouth-Hitchcock Medical Center
    Study site
    Northwestern Memorial Hospital
    Registry record
    NCT05612347 · updated
  26. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #26
    Registry record
    NCT05176483 · updated
  27. PRE-ISPY Phase I/II Oncology Platform Program

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    QuantumLeap Healthcare Collaborative
    Study site
    The University of Chicago Medicine Comprehensive Cancer Center
    Registry record
    NCT05868226 · updated
  28. Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Chicago
    Study site
    University of Chicago
    Registry record
    NCT06349590 · updated
  29. A Phase 1/1b Study of IAM1363 in HER2 Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study site
    University of Chicago
    Registry record
    NCT06253871 · updated
  30. Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Amgen
    Study site
    Insight Research Institute
    Registry record
    NCT06252649 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Chicago, IL on ClinicalTrials.gov.

Ask about studies near Chicago

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call